Alector disclosed that a GSK-partnered antibody failed a Phase III trial in frontotemporal dementia, producing no meaningful effect on clinical endpoints despite biomarker changes. The biotech said it will end development of the asset, halve its workforce and initiate a strategic refocus. Management also announced senior departures and plans to reassess the company’s R&D footprint and cash runway.